Literature DB >> 20634701

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

Zixin Hu1, Daniel R Kuritzkes.   

Abstract

Raltegravir resistance is conferred by mutations at integrase codons 143, 148, and 155 together with associated secondary mutations. The N155H mutants emerge first, and are eventually replaced by Q148H mutants, usually in combination with G140S. These mutations have different effects on susceptibility and replication capacity, but data on the relative fitness of RAL-resistant viruses are limited. To understand the impact of the different RAL resistance pathways on viral fitness, mutations at integrase codons 74, 92, 138, 140, 148, 155, and/or 163 were introduced into HIV-1NL4-3 by site-directed mutagenesis and expressed in recombinant viruses. Relative fitness and drug susceptibility were determined in the absence or presence of RAL. In the absence of drug, RAL-resistant mutants were less fit than wild type, and the Q148H mutant was significantly less fit than the N155H mutant. Fitness was partially restored by the presence of additional RAL resistance mutations at positions G140S and E92Q or E138K, respectively. In the presence of RAL, the N155H mutant remained fitter than the Q148H mutant, but the G140S/Q148H double mutant was fitter than single mutants or the E92Q/N155H double mutant. These findings correspond well with the clinical trials data and help explain the temporal pattern of RAL resistance evolution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634701      PMCID: PMC2943977          DOI: 10.1097/QAI.0b013e3181e9a87a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

1.  HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer.

Authors:  A Engelman; K Mizuuchi; R Craigie
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

2.  Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

Authors:  Olivier Delelis; Sylvain Thierry; Frédéric Subra; Françoise Simon; Isabelle Malet; Chakib Alloui; Sophie Sayon; Vincent Calvez; Eric Deprez; Anne-Geneviève Marcelin; Luba Tchertanov; Jean-François Mouscadet
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

3.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

4.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.

Authors:  Peter J King; Deborah J Lee; Ryan A Reinke; Joseph G Victoria; Keola Beale; W Edward Robinson
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

6.  A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.

Authors:  J Lu; D R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

7.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.

Authors:  Y Goldgur; R Craigie; G H Cohen; T Fujiwara; T Yoshinaga; T Fujishita; H Sugimoto; T Endo; H Murai; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 8.  Molecular mechanisms in retrovirus DNA integration.

Authors:  E Asante-Appiah; A M Skalka
Journal:  Antiviral Res       Date:  1997-12       Impact factor: 5.970

9.  Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication.

Authors:  P M Cannon; E D Byles; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells.

Authors:  R L LaFemina; C L Schneider; H L Robbins; P L Callahan; K LeGrow; E Roth; W A Schleif; E A Emini
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  39 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Authors:  Mark A Brockman; Denis R Chopera; Alex Olvera; Chanson J Brumme; Jennifer Sela; Tristan J Markle; Eric Martin; Jonathan M Carlson; Anh Q Le; Rachel McGovern; Peter K Cheung; Anthony D Kelleher; Heiko Jessen; Martin Markowitz; Eric Rosenberg; Nicole Frahm; Jorge Sanchez; Simon Mallal; Mina John; P Richard Harrigan; David Heckerman; Christian Brander; Bruce D Walker; Zabrina L Brumme
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

3.  The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Authors:  Saleta Sierra; Nadine Lübke; Hauke Walter; Eugen Schülter; Stefan Reuter; Gerd Fätkenheuer; Markus Bickel; Hugo da Silva; Rolf Kaiser; Stefan Esser
Journal:  Med Microbiol Immunol       Date:  2011-04-08       Impact factor: 3.402

4.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

5.  Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.

Authors:  Szu-Min Hsieh; Sung-Ching Pan; Sui-Yuan Chang; Chien-Ching Hung; Wang-Huei Sheng; Mao-Yuan Chen; Shan-Chwen Chang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-15       Impact factor: 2.205

6.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

7.  Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.

Authors:  Signe Fransen; Soumi Gupta; Arne Frantzell; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

8.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

9.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

10.  Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.